BlackRock
SPRY icon

BlackRock’s ARS Pharmaceuticals SPRY Stock Holding History

BlackRock’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.5M Buy
5,311,319
+299,065
+6% +$2.57M ﹤0.01% 2769
2026
Q1 		$40.2M Sell
5,012,254
-73,063
-1% -$700K ﹤0.01% 2650
2025
Q4 		$59.2M Buy
5,085,317
+253,990
+5% +$2.47M ﹤0.01% 2414
2025
Q3 		$48.6M Buy
4,831,327
+407,863
+9% +$5.85M ﹤0.01% 2520
2025
Q2 		$77.2M Buy
4,423,464
+124,476
+3% +$1.8M ﹤0.01% 2216
2025
Q1 		$54.1M Sell
4,298,988
-275,503
-6% -$3.31M ﹤0.01% 2334
2024
Q4 		$48.3M Buy
4,574,491
+328,517
+8% +$4.6M ﹤0.01% 2473
2024
Q3 		$61.6M Buy
4,245,974
+161,635
+4% +$1.92M ﹤0.01% 2350
2024
Q2 		$34.8M Buy
4,084,339
+1,426,100
+54% +$12.7M ﹤0.01% 2637
2024
Q1 		$27.2M Buy
2,658,239
+20,690
+0.8% +$154K ﹤0.01% 2816
2023
Q4 		$14.5M Buy
2,637,549
+70,765
+3% +$310K ﹤0.01% 3195
2023
Q3 		$9.7M Buy
2,566,784
+305,864
+14% +$2.01M ﹤0.01% 3351
2023
Q2 		$15.1M Buy
2,260,920
+1,142,355
+102% +$7.62M ﹤0.01% 3200
2023
Q1 		$7.28M Buy
1,118,565
+215,020
+24% +$1.65M ﹤0.01% 3473
2022
Q4 		$7.71M Buy
903,545
+175,841
+24% +$1.14M ﹤0.01% 3512
2022
Q3 		$3.84M Buy
727,704
+19,859
+3% +$97.9K ﹤0.01% 3873
2022
Q2 		$3M Sell
707,845
-899,655
-56% -$3.14M ﹤0.01% 4059
2022
Q1 		$5.64M Buy
1,607,500
+28,213
+2% +$123K ﹤0.01% 3895
2021
Q4 		$10.5M Buy
1,579,287
+351,626
+29% +$2.86M ﹤0.01% 3643
2021
Q3 		$12.3M Buy
1,227,661
+348,296
+40% +$8.59M ﹤0.01% 3581
2021
Q2 		$27.2M Sell
879,365
-339,903
-28% -$10.9M ﹤0.01% 3115
2021
Q1 		$53.2M Buy
1,219,268
+829,107
+213% +$39.2M ﹤0.01% 2571
2020
Q4 		$18.1M Buy
+390,161
New +$13M ﹤0.01% 3061

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock's SPRY Position: Q2 2026 in Review

BlackRock increased its ARS Pharmaceuticals (SPRY) stake by 6% in Q2 2026, buying an estimated $2.57M and bringing the position to 5,311,319 shares worth $42.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2769.

BlackRock first reported a position in SPRY in Q4 2020 and has held it in 23 quarters since. The position peaked at $77.2M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • BlackRock held 5,311,319 shares of ARS Pharmaceuticals worth $42.5M as of Q2 2026.
  • BlackRock bought 299,065 ARS Pharmaceuticals shares in Q2 2026, an estimated $2.57M.
  • ARS Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2769 holding.
  • BlackRock first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's ARS Pharmaceuticals position peaked at $77.2M in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.